Radical cure for falciparum malaria in co-endemic areas

在恶性疟原虫和间日疟原虫这两种主要疟疾共同流行的地区，伯氨喹是目前唯一可用于治疗休眠肝型间日疟原虫疟疾并因此减少复发的药物，仅用于急性间日疟原虫疟疾患者。然而，越来越多的证据表明，恶性疟原虫感染增加了间日疟原虫复发的风险。因此，我们建议评估伯氨喹对恶性疟原虫单一感染患者的益处。

In areas co-endemic for the two main species of malaria P.falciparum and P.vivax, Primaquine the only drug currently available to treat the dormant liver forms of P. vivax malaria and therefore reduce relapses is only used in patients presenting with acute vivax malaria. However there is mounting evidence that P. falciparum infection increases the risk of P. vivax relapse. Therefore we propose to assess the benefit of administering Primaquine to patients with P. falciparum mono-infection.